Cuprina Holdings (Cayman) Limited reports developments tied to its biomedical product portfolio for chronic wounds, infertility, medical waste recycling and cosmeceuticals. Company updates focus on MEDIFLY, its medical-grade maggot debridement therapy for chronic wound management, including regulatory classification and regional commercialization steps.
Recurring news also covers product and technology diversification, including IVF media production capabilities in Singapore, iodine-based wound care collaborations, and exclusive licensing rights for high-temperature steam treatment technology used to sterilize, decontaminate and recycle plastic-based medical waste. Cuprina's announcements also include scientific advisory activity, public-company communications, financial results and Nasdaq listing-compliance matters.
Cuprina (Nasdaq: CUPR) signed agreements to acquire full ownership of East Coast Podiatry and Orchard Clinic for approximately S$4.0 million. The acquisition covers their operating companies, East Coast Podiatry Centre and Orchard Clinic Management, through Cuprina’s wholly owned subsidiary.
Consideration comprises S$3.0 million in cash: approximately S$0.5 million paid at signing, S$1.35 million payable at closing and S$1.15 million deferred over two years. Another S$1.0 million in Class A ordinary shares will be subject to a lock-up. Cuprina expects completion on or before November 1, 2026, subject to customary closing conditions, followed by financial consolidation. The target group reported FY2025 unaudited revenue of S$9.1 million and normalized EBITDA—earnings before interest, tax, depreciation and amortization—of S$1.2 million. These management-account figures may change after audit.
Cuprina Holdings (Cayman) (Nasdaq: CUPR) closed the sale of 648,373 additional Class A ordinary shares through its underwriter’s over-allotment option.
The option was exercised in full at $1.15 per share, generating approximately $745,629 in gross proceeds. Aggregate offering gross proceeds reached approximately $5,716,491, before underwriting discounts, commissions and estimated offering expenses. Cuprina intends to use net proceeds for new businesses, research and development, market expansion, brand awareness, equipment and infrastructure, and working capital. R. F. Lafferty acted as sole book-running manager.
Cuprina Holdings (CUPR) closed a public offering of 4,322,489 Class A Ordinary Shares at $1.15 per share on September 17, 2026, raising approximately $4.97 million in gross proceeds before fees.
The company granted the underwriter a 45‑day option to buy up to an additional 648,373 shares at the same price, which would increase gross proceeds to about $5.72 million if fully exercised. Cuprina plans to use net proceeds for expansion into new businesses and markets, R&D to broaden its product portfolio, brand building, equipment and infrastructure investment, and general working capital. R. F. Lafferty & Co. acted as sole book‑running manager. The offering was made under an SEC‑effective Form F‑1 registration statement and is available only by prospectus.
Cuprina Holdings (CUPR) priced a firm commitment public offering of 4,322,489 Class A ordinary shares at $1.15 per share on September 16, 2026.
The offering is expected to generate approximately $4.97 million in gross proceeds before underwriting discounts and expenses. The company granted the underwriter a 45-day option to purchase up to 648,373 additional shares at the same price, which would increase gross proceeds to about $5.72 million if fully exercised. The offering is expected to close on or about September 17, 2026, subject to customary closing conditions, and is made under an effective SEC Form F-1 registration statement.
Cuprina (Nasdaq:CUPR) received U.S. FDA 510(k) clearance for MEDIFLY Maggots, a Lucilia cuprina maggot debridement therapy product. It is, to the company’s knowledge, the first U.S.-cleared MDT product using this species.
The product is cleared to debride non-healing necrotic skin and soft tissue wounds and gives Cuprina U.S. commercial rights to both Lucilia sericata and Lucilia cuprina MDT species, supporting global registration efforts.
Cuprina Holdings (Nasdaq: CUPR) announced it regained compliance with Nasdaq Capital Market listing requirements as of June 11, 2026. The company previously faced a Staff Delisting Determination for failing the $1.00 minimum bid price rule, but now meets the Minimum Bid Requirement and avoids a scheduled July 7, 2026 hearing.
Cuprina Holdings (Nasdaq:CUPR) has completed a reverse stock split effective May 27, 2026 and requested a hearing before the Nasdaq Hearings Panel to maintain its Nasdaq Capital Market listing.
The move follows a Nasdaq determination to delist after CUPR failed the $1.00 minimum bid price requirement by May 26, 2026. The hearing request keeps trading and listing active pending the Panel’s decision, and the company expects the share consolidation to help restore bid-price compliance.
Cuprina Holdings (Nasdaq:CUPR) will implement a 1-for-8 share consolidation of its Class A and Class B ordinary shares, effective on or around May 27, 2026. Post-consolidation, Class A shares will continue trading on Nasdaq under symbol CUPR with new CUSIP G2592E110.
The action aims to help Cuprina regain compliance with Nasdaq Rule 5550(a)(2) and maintain its listing. Every 8 shares at par value US$0.001 will convert into 1 share at par value US$0.008, with fractional shares rounded up. Board approval occurred on April 21, 2026 and shareholder approval on May 14, 2026.
Cuprina (Nasdaq:CUPR) announced a regulatory milestone and advisory board expansion on March 11, 2026. Cuprina’s 49% associate, Cuprina MENA, received SFDA product classification for MEDIFLY as a Medical Device–Drug combination, enabling finalization of Saudi technical requirements for commercial distribution.
The company also appointed Dr. Enming Yong to its Medical & Scientific Advisory Board to provide clinical oversight, protocol review, and endocrinology expertise. Cuprina reported regional clinical engagement activities in Hong Kong and Singapore and held its inaugural advisory board meeting on March 2, 2026.
Cuprina Holdings (Nasdaq: CUPR) reported results for the six months ended June 30, 2025, showing revenue of $18,040 (down 40% YoY) and a net loss of $1,528,121 (or $(.08) per share).
The company completed an IVF media production facility with ISO 13485 certification, secured an FDA-approved license for medical maggots in the U.S., advanced a MENA maggot-manufacturing lab, licensed UNIDO/GEF medical-waste recycling technology for Southeast Asia, and signed joint ventures for iodine-based antiseptics.
Cash was $3.22M at June 30, 2025; Cuprina projects 2026 revenue of $1.0–$1.5M and plans multiple commercial rollouts and human clinical trials.